Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bevanolol is a cardioselective beta-1 adrenergic receptor antagonist with additional alpha-1 adrenergic blocking activity. It is primarily indicated for the management of hypertension and angina pectoris. By blocking beta-1 receptors in the heart, it reduces heart rate and myocardial contractility, while its alpha-1 blocking properties contribute to peripheral vasodilation, collectively lowering blood pressure. Bevanolol has been noted in clinical research for its potential impact on sexual function in hypertensive patients compared to other beta-blockers. It was originally developed by Warner-Lambert and is marketed in several countries, including China and Japan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bevanolol.